Table 2. Meta-analysis results of the 4 novel psoriasis susceptibility loci.

Gene	SNP	Chr	BP.B37	RA	RAF		Stage	European		Chinese		Combined All
					EUR	CHN		P	OR(95%CI)	P	OR(95%CI)	P	OR(95%CI)	PQ
TP63	rs28512356	3	189615475	C	0.799	0.826	GWAS	9.99E−06	1.20 (1.11–1.30)	9.52E−01	1.00 (0.88–1.13)	7.70E−06	1.10 (1.06–1.15)	9.62E−04
							Validation	9.30E−04	1.15 (1.06–1.25)	4.93E−01	1.03 (0.96–1.10)
							Combined	4.31E−08	1.17 (1.11–1.24)	5.68E−01	1.02 (0.96–1.08)
COG6	rs34394770	13	40333369	T	0.643	0.763	GWAS	5.55E−07	1.18 (1.11–1.26)	1.22E−01	1.10 (0.98–1.23)	4.87E−08	1.11 (1.07–1.15)	2.04E−02
							Validation	8.21E−03	1.12 (1.03–1.21)	1.43E−01	1.05 (0.98–1.11)
							Combined	2.65E−08	1.16 (1.10–1.22)	4.63E−02	1.06 (1.00–1.12)
LOC144817	rs9533962	13	45334194	C	0.406	0.449	GWAS	1.76E−03	1.11 (1.04–1.18)	3.93E−05	1.23 (1.12–1.36)	7.53E−11	1.12 (1.08–1.15)	2.91E−01
							Validation	1.60E−06	1.16 (1.09–1.24)	5.30E−02	1.06 (1.00–1.12)
							Combined	1.93E−08	1.14 (1.09–1.19)	2.25E−04	1.09 (1.04–1.15)
RUNX1	rs8128234	21	36470865	T	0.197	0.111	GWAS	1.82E−05	1.19 (1.10–1.28)	8.98E−02	1.15 (0.98–1.34)	5.99E−08	1.13 (1.08–1.18)	4.23E−02
							Validation	4.77E−04	1.15 (1.06–1.24)	3.35E−01	1.04 (0.96–1.13)
							Combined	3.74E−08	1.17 (1.11–1.23)	9.88E−02	1.06 (0.99–1.14)

BP.B37, position based on NCBI build 37; CHN, Han Chinese samples; Chr, chromosome; GWAS, genome-wide association study; EUR, European samples; RA, risk alleles; RAF, risk allele's frequencies; OR, odds ratio; P: association P values in logistic regression test (alleles dosages in GWAS studies); 95% CI, 95% confidence interval; P_Q: P values of heterogeneity test; SNP, single-nucleotide polymorphism.